Non-Proliferative Diabetic Retinopathy Market Report 2026

The non-proliferative diabetic retinopathy market size has grown strongly in recent years. It will grow from $2.83 billion in 2025 to $3.06 billion in 2026 at a compound annual growth rate (CAGR) of 8%. The growth in the historic period can be attributed to high prevalence of diabetes, limited awareness of retinal complications, reliance on conventional laser treatments, low adoption of intravitreal injections, insufficient screening infrastructure.

The non-proliferative diabetic retinopathy market size is expected to see strong growth in the next few years. It will grow to $3.98 billion in 2030 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to rising prevalence of diabetic retinopathy, increasing adoption of anti-vegf and steroid therapies, expansion of ophthalmology clinics and specialty centers, growth in advanced retinal imaging technologies, improving patient awareness and early diagnosis programs. Major trends in the forecast period include rising adoption of anti-vegf therapy in npdr, increasing use of intraocular steroid injections, growing implementation of advanced laser surgery techniques, expanding deployment of vitrectomy procedures, advancing integration of ai-powered retinal imaging and diagnosis.

The rising prevalence of diabetes is expected to drive the growth of the non-proliferative diabetic retinopathy (NPDR) market in the coming years. Diabetes, a chronic metabolic disorder characterized by elevated blood glucose due to insufficient insulin production or insulin resistance, damages the retinal blood vessels over time, leading to NPDR, vision impairment, and potential blindness. Factors such as sedentary lifestyles, unhealthy diets, and genetic predispositions are contributing to the growing diabetes population. For instance, in June 2024, according to the National Health Service (NHS), a UK-based government agency, over 549,000 additional individuals in England were identified at risk of developing type 2 diabetes in 2023, raising the total number of people with non-diabetic hyperglycemia registered with a GP to 3,615,330 - nearly a 20% increase from 3,065,825 in 2022. Therefore, the increasing prevalence of diabetes is driving the NPDR market growth.

Major companies in the NPDR market are focusing on advanced clinical solutions, such as Phase 3 registrational trials, to strengthen treatment validation and support regulatory approval. Phase 3 registrational trials involve enrolling and randomizing patients into pivotal late-stage studies to generate comprehensive efficacy and safety data required for market authorization. For example, in November 2025, Ocular Therapeutix, a US-based biopharmaceutical company specializing in retinal diseases, announced the first patient randomization in the HELIOS-3 Phase 3 trial evaluating AXPAXLI (OTX-TKI) for NPDR. AXPAXLI is an investigational bioresorbable intravitreal hydrogel containing axitinib, a tyrosine kinase inhibitor with anti-angiogenic activity, designed to provide sustained therapy with fewer injections. The HELIOS-3 and HELIOS-2 trials use a novel ordinal ≥2-step Diabetic Retinopathy Severity Score (DRSS) improvement as the primary endpoint and include patients with non-center-involved diabetic macular edema (non-CI-DME), positioning AXPAXLI as a potentially transformative therapy for durable NPDR management.

In March 2024, Sandoz, a Switzerland-based provider of generic and biosimilar medicines, acquired the ophthalmology subsidiary of Coherus BioSciences Inc., including the CIMERLI (ranibizumab-eqrn) business, for $170 million. Through this acquisition, Sandoz aims to strengthen its U.S. ophthalmology and biosimilar portfolio by expanding treatment options for retinal diseases such as NPDR. Coherus BioSciences Inc., a US-based biopharmaceutical company, previously commercialized the CIMERLI biosimilar for retinal disorders.

Major companies operating in the non-proliferative diabetic retinopathy market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Abbott Laboratories, Novartis AG, Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Genentech Inc., Carl Zeiss Meditec AG, ZEISS Group, Santen Pharmaceutical Co. Ltd., Santen Inc., Topcon Corporation, Lumenis Ltd., Alimera Science, Ocular Therapeutix Inc., Acucela Inc., Kowa Company Ltd.

North America was the largest region in the non-proliferative diabetic retinopathy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-proliferative diabetic retinopathy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the non-proliferative diabetic retinopathy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the non-proliferative diabetic retinopathy market by increasing costs of imported anti-vegf drugs, steroid implants, laser equipment, and vitrectomy instruments. Segments such as anti-vegf therapy, laser surgery, and vitrectomy are most affected, with north america, europe, and asia-pacific experiencing the highest cost pressures. While tariffs increase procurement costs and lead times, they also encourage local production, drive innovation in cost-effective treatment solutions, and strengthen domestic ophthalmic healthcare supply chains.

The non-proliferative diabetic retinopathy market research report is one of a series of new reports that provides non-proliferative diabetic retinopathy market statistics, including non-proliferative diabetic retinopathy industry global market size, regional shares, competitors with a non-proliferative diabetic retinopathy market share, detailed non-proliferative diabetic retinopathy market segments, market trends and opportunities, and any further data you may need to thrive in the non-proliferative diabetic retinopathy industry. This non-proliferative diabetic retinopathy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Non-proliferative diabetic retinopathy (NPDR) is a common complication of diabetes mellitus that affects the retina, the light-sensitive tissue at the back of the eye. NPDR is marked by changes in retinal blood vessels caused by prolonged high blood sugar (hyperglycemia) associated with diabetes. Management involves a combination of medical treatments, lifestyle modifications, and regular eye examinations to prevent disease progression and protect vision.

The main treatment options for non-proliferative diabetic retinopathy include anti-vascular endothelial growth factor (VEGF) therapy, intraocular steroid injections, laser surgery, and vitrectomy. Anti-VEGF therapy uses medications that inhibit vascular endothelial growth factor (VEGF) to prevent abnormal blood vessel growth in the retina. Treatments are applied across different severity levels, including mild, moderate, and severe NPDR, and are provided in hospitals, specialty clinics, ambulatory surgical centers, and other healthcare settings.

The non-proliferative diabetic retinopathy (NPDR) market consists of revenues earned by entities by providing services such as ophthalmological consultations, optometric services, contract research services, and counselling services. The market value includes the value of related goods sold by the service provider or included within the service offering. The non-proliferative diabetic retinopathy (NPDR) market also includes sales of fundus cameras, optical coherence tomography (OCT) machines, laser photocoagulation equipment, and injections. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.